This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy
by Zacks Equity Research
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
by Zacks Equity Research
The heavy selling pressure might have exhausted for PepGen (PEPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, PepGen (PEPG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Best Momentum Stocks to Buy for April 25th
by Zacks Equity Research
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
New Strong Buy Stocks for April 25th
by Zacks Equity Research
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for PepGen, Inc. (PEPG) points to a 48.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
PepGen, Inc. (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
by Zacks Equity Research
PepGen (PEPG) shares fall after FDA places clinical hold on a study evaluating potential treatment for myotonic dystrophy.
PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
PepGen, Inc. (PEPG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going
by Zacks Equity Research
PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength
by Zacks Equity Research
PepGen, Inc. (PEPG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 50.4% upside potential for PepGen, Inc. (PEPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'
by Zacks Equity Research
PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 68.1% in PepGen, Inc. (PEPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.